Status:
NO_LONGER_AVAILABLE
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Organ Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties
Detailed Description
This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression. The objectives are to facilitate the management of patients on maintenance immunosup...
Eligibility Criteria
Inclusion
- Male or female recipients of solid organ transplants
- Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
- Currently on investigational drug everolimus (RAD) therapy
Exclusion
- Inability or unwillingness to comply with immunosuppressive regimen.
- Pregnancy.
- History of acute organ rejection within the last 3 months.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00149981
Last Update
September 9 2019
Active Locations (153)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Birmingham, Alabama, United States, 35233
2
Novartis Investigative Site
Birmingham, Alabama, United States, 35294-0006
3
Novartis Investigative Site
Mobile, Alabama, United States, 36617
4
Novartis Investigative Site
Los Angeles, California, United States, 90024